glp-1 psoriatic arthritis Which PsO Patients Can Benefit From GLP-1RAs? GLP-1 and Inflammation: How These
Description
As our knowledge of GLP-1 biology advances and novel therapeutic innovations arise, these agents are expected to assume a progressively pivotal role in the management of metabolic disorders and their related complications, ultimately enhancing patient outcomes across various disease states
Signaling architecture of the glucagon-like peptide-1 receptor
A systematic review and meta-analysis of 55 RCTs (106,395 participants) published in Gastroenterology in 2025 confirmed elevated risk of cholelithiasis, cholecystitis, and gastrointestinal events across the class
PlexusDx also offers oral semaglutide (starting at $249/mo) as an alternative delivery method
Source: published Phase 2 and Phase 3 trial data (cross-study, not head-to-head)
doi: 10.1210/clinem/dgz140 174 Ten KulveJSVeltmanDJVan BloemendaalLGrootPFCRuhHGBarkhofFet al
